Cargando…
Adjuvant and neoadjuvant small-molecule targeted therapy in high-risk renal cell carcinoma
BACKGROUND: Non-localized renal cell carcinoma (rcc) carries a poor prognosis with a significant risk of mortality for patients. Traditionally, interleukin-2 and interferon alfa have been administered in this setting, with high toxicity and limited improvement in cancer-specific survival. However, n...
| Autores principales: | , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Multimed Inc.
2009
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687799/ https://www.ncbi.nlm.nih.gov/pubmed/19478895 |